Clinical trial NCT03854864: Evaluation by Oncologists of Strategies for the Prevention and Treatment of Chemotherapy-induced Peripheral Neuropathies
Official title: Evaluation by Oncologists of Strategies for the Prevention and Treatment of Chemotherapy-induced Peripheral Neuropathies: Observational and Cross-sectional Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Chemotherapy-induced Peripheral Neuropathy
Keywords: Peripheral Nervous System Diseases
Oncologists
Lead sponsor: University Hospital, Clermont-Ferrand
Sponsor class: OTHER
Collaborators: name: UFR de Pharmacie (Clermont-Ferrand)
First posted: 2019-02-26
Enrollment: 216
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: oncologist

Brief summary: Chemotherapy induced peripheral neuropathy (CIPN) is one of the most deleterious adverse effect of neurotoxic anticancer drugs affecting up to 40% of patients. These neurotoxic anticancer agents include mainly: cisplatin (bronchopulmonary cancers), oxaliplatin (colorectal cancers), paclitaxel (breast cancers and bronchopulmonary cancers), docetaxel (breast cancers and bronchopulmonary cancers) and bortezomib (multiple myeloma).

CIPN affects not only the quality of life of patients, it also has a major impact on oncology strategy, forcing oncologists to reduce dose-intensity, to stop an ongoing chemotherapy regimen and to change therapeutic strategies, with a risk of compromising patients' survival.

There is no real preventive or curative treatment (except duloxetine) for CIPN and it is not known what is the practice of oncologists in France? However, it is essential to know the degree of sensitivity of oncologists to this problem and their practice.

With this study, the investigators propose to assess the current practices of management by oncologists in France in 2019, for any type of practitioners of university hospital, or general hospital, for all type of neurotoxic anticancer drugs.

Detailed description: This observational and cross-sectional study will be conducted as a survey using the REDCap software and the response to this survey will be done online, in real time, with an automatic, secure and centralized data collection (CHU Clermont-Ferrand).

French oncologist will be contacted by email thanks to the regional cancer networks. Answer to the survey will be done online.

Eligibility criteria: Inclusion Criteria:

* Oncologist

Exclusion Criteria:

* pain physician

Primary outcomes:
measure: Treatment strategy for CIPN
timeFrame: at day 1
Secondary outcomes:
measure: Perception of effectiveness of the treatments used
timeFrame: at day 1
measure: Perception of safety of the treatments used to treat CIPN
timeFrame: at day 1
measure: Treatment strategy for CIPN prevention
timeFrame: at day 1
measure: Estimation by the oncologist of the percentage of patients affected by CIPN
timeFrame: at day 1
measure: Proportion of assessments of the CIPN severity performed by the oncologist using a specific questionnaire
timeFrame: at day 1
measure: Proportion of CIPN assessments performed by the oncologist with a clinical examination
timeFrame: at day 1
measure: Proportion of CIPN assessments performed by a neurological examination (neurologist)
timeFrame: at day 1
measure: Age of oncologists
timeFrame: at day 1
measure: Sex of oncologists
timeFrame: at day 1
measure: Organ or system speciality of oncologists
timeFrame: at day 1
measure: Number of chemotherapy prescriptions
timeFrame: at day 1
measure: Types of neurotoxic anticancer drugs prescribed
timeFrame: at day 1
measure: Working place
timeFrame: at day 1
Other outcomes:
Locations:
city: Clermont-Ferrand
country: France
facility: Chu Clermont-Ferrand
Study officials:
affiliation: University Hospital, Clermont-Ferrand
name: David BALAYSSAC
role: PRINCIPAL_INVESTIGATOR
References:
citation: Selvy M, Pereira B, Kerckhove N, Busserolles J, Farsi F, Guastella V, Merle P, Pezet D, Balayssac D. Prevention, diagnosis and management of chemotherapy-induced peripheral neuropathy: a cross-sectional study of French oncologists' professional practices. Support Care Cancer. 2021 Jul;29(7):4033-4043. doi: 10.1007/s00520-020-05928-6. Epub 2021 Jan 5.